- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
Détention brevets de la classe A61K 39/145
Brevets de cette classe: 2893
Historique des publications depuis 10 ans
|
189
|
190
|
168
|
196
|
180
|
157
|
164
|
179
|
214
|
145
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Glaxosmithkline Biologicals S.A. | 1654 |
80 |
| Seqirus UK Limited | 430 |
59 |
| Icahn School of Medicine at Mount Sinai | 966 |
48 |
| Curevac SE | 269 |
44 |
| Wisconsin Alumni Research Foundation | 3890 |
43 |
| University of Georgia Research Foundation, Inc. | 1045 |
40 |
| Sanofi Pasteur Inc. | 377 |
39 |
| Janssen Vaccines & Prevention B.V. | 311 |
34 |
| Modernatx, Inc. | 1297 |
31 |
| Novartis AG | 10674 |
30 |
| The Trustees of the University of Pennsylvania | 4377 |
30 |
| Aramis Biotechnologies Inc. | 57 |
28 |
| FluGen, Inc. | 36 |
26 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2895 |
25 |
| University of Pittsburgh - Of the Commonwealth System of Higher Education | 3204 |
24 |
| Academia Sinica | 945 |
23 |
| Longhorn Vaccines and Diagnostics, LLC | 90 |
22 |
| University of Rochester | 1322 |
22 |
| Intervet Inc. | 905 |
21 |
| Novavax, Inc. | 164 |
21 |
| Autres propriétaires | 2203 |